The primary aim of the LEGACy project is to improve gastric cancer outcomes by applying personalized medicine at the three levels of prevention in EU and CELAC populations.
The CELAC and European consortium for a personalized medicine approach to Gastric Cancer (LEGACy) is a partnership between 11 organisations from Argentina, Belgium, Chile, Germany, Mexico, The Netherlands, Paraguay, Portugal and Spain.
Gastric cancer is the third leading cause of cancer death in both sexes worldwide. LEGACy will develop a personalized medicine approach that will improve the prognosis of gastric cancer.
Access to clinical trials for gastrointestinal malignancies across bordersMay 23 @ 15:00 - 17:00
Acceso a ensayos clínicos para tumores gastrointestinales cruzandoMay 26 @ 15:00 - 17:00